PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2010; 5(12): e15154.
Published online 2010 December 3. doi:  10.1371/journal.pone.0015154
PMCID: PMC2997082

The Type of Responder T-Cell Has a Significant Impact in a Human In Vitro Suppression Assay

Derya Unutmaz, Editor

Abstract

Background

In type 1 diabetes (T1D), a prototypic autoimmune disease, effector T cells destroy beta cells. Normally, CD4+CD25+high, or natural regulatory T cells (Tregs), counter this assault. In autoimmunity, the failure to suppress CD4+CD25low T cells is important for disease development. However, both Treg dysfunction and hyperactive responder T-cell proliferation contribute to disease.

Methods/Principal Findings

We investigated human CD4+CD25low T cells and compared them to CD4+CD25- T cells in otherwise equivalent in vitro proliferative conditions. We then asked whether these differences in suppression are exacerbated in T1D. In both single and co-culture with Tregs, the CD4+CD25low T cells divided more rapidly than CD4+CD25- T cells, which manifests as increased proliferation/reduced suppression. Time-course experiments showed that this difference could be explained by higher IL-2 production from CD4+CD25low compared to CD4+CD25- T cells. There was also a significant increase in CD4+CD25low T-cell proliferation compared to CD4+CD25- T cells during suppression assays from RO T1D and at-risk subjects (n = 28, p = 0.015 and p = 0.024 respectively).

Conclusions/Significance

The in vitro dual suppression assays proposed here could highlight the impaired sensitivity of certain responder T cells to the suppressive effect of Tregs in human autoimmune diseases.

Introduction

The immune system of a healthy organism maintains immune balance between tolerance and active response. Under normal physiological conditions, the immune balance is a tightly regulated network of several types of immune cells. If this is perturbed, the response can be either inefficient (as in cancer) or, conversely, over-reactive, resulting in conditions such as autoimmunity. Maintaining peripheral self-tolerance by reducing effector T cell function (suppression) is crucial in preventing autoimmunity. Several mechanisms have been proposed, including induction of T-cell anergy, immunological ignorance and control of the expression of co-stimulatory molecules necessary for activation of naïve, autoreactive T cells. In addition, regulatory T cells impart direct suppression of effector function of autoaggressive T cells [1]. One regulatory subset that has been well characterized, expresses cell-surface IL-2Rα-chains (CD25) constitutively [2]. Adoptive transfer of these CD4+CD25high regulatory T cells (Tregs) in animal models has been shown to offer protection from several autoimmune diseases [3], [4], [5]. Thus, Tregs are highly specialized cells that play a pivotal role in the control of autoimmunity.

In human subjects 1–3% of the CD4+ T cell population expressing the highest levels of surface CD25 demonstrates regulatory properties [6]. These cells constitutively express CD25 and Foxp3 and show increased expression of CTLA-4, HLA DR, GITR and CD45RO, among other markers, although it has been proven recently that resting nTregs express CD45RA [7]. However, these surface markers are also expressed by activated T cells. Tregs differ from activated T cells by decreased expression of CD127 [8], which somewhat increases confidence in the isolation of Tregs and in their enumeration. Nevertheless, a population of CD4+CD25+CD127low/- T cells does not exhibit enhanced suppressor function compared to CD4+CD25high T cells in our hands (Glisic S, unpublished) as well as in studies of Miyara et al [7]. Therefore, the unique property so far known to distinguish Tregs from non-Tregs is their capacity to suppress proliferation of other T cells. Suppression assays can be performed both in vivo [9] and in vitro, the latter being the only option for human studies. The in vitro assay usually involves responder T cells, antigen-presenting cells (APC) and Tregs. Although our understanding of suppression is increasing [10], the exact relationship between cells in a suppression assay (both in vivo and in vitro) has not been completely understood. A functional defect of Tregs was reported in many autoimmune diseases (AD): SLE [11], rheumatoid arthritis (RA) [12], multiple sclerosis [13] and type 1 diabetes [14]. However, evidence is emerging that Treg dysfunction cannot fully explain decreased suppression of responder T cell proliferation in AD. Recent reports showed that impaired sensitivity of responder T cells (including autoreactive cells) to suppression by Tregs led to a defective suppression of their proliferation in disease state in NOD mice and human subjects with SLE and T1D [15], [16], [17]. The importance of the presence of antigen-presenting cells (APC) in in vitro suppression assay was also recently shown [18]. This report suggested that APCs could be a major source of defects in suppression in T1D. Other reports proved the important role of co-stimulatory ligands on APC (CD28:B7, 4-1BB:4-IBBL, ICOS:CD275, CD40:CD40L) which promote proper stimulation of T cells, and, hence, suppression of responders' proliferation [19], [20], [21]. In addition, the type and strength of stimulation used in an in vitro suppression assay is known to affect suppression in both healthy and diseased states [6], [22].

Such variability in the human suppression assay prompted us to perform a comprehensive study investigating the aforementioned factors. After we found the optimal in vitro conditions using cells isolated from human leukopacks (enriched leukocytes from whole blood) obtained from anonymous donors, we performed a study involving T1D-related subject groups to test the hypothesis that Tregs cannot suppress two different responder T cell subsets equally well (CD4+CD25- and CD4+CD25low). We expected the difference in suppressive potential on the two cell subsets to be amplified in subjects affected with or at risk to develop T1D compared to control subjects.

Results generated in this study suggest that (i) the type of the responder T cells set up in an in vitro suppression assay has the greatest impact on suppression by Tregs (ii) CD4+CD25low T cells divide more than CD4+CD25- T cells and are more difficult to suppress; (iii) the two cell types have different dynamics of IL-2 production, proliferation and death.

Results

The type of responder T cell has the greatest impact in a T-cell suppression assay

CD4+CD25-, CD4+CD25low and CD4+CD25high T cells were isolated from human PBMC by flow sorting (Figure 1A). Using FACS, the purity of these isolated cells was analyzed further for CD25 expression (Figure 1A), proliferation (Figure 1B) and intracellular Foxp3 expression (Figure 1C). Foxp3 is usually used as a marker for recognition of Tregs, however, we measured its intracellular presence in all three cell types. FACS-isolated CD4+CD25- and CD4+CD25low were treated further as separate responder T cell subsets. We looked at the expression of different surface markers and measured cytokines produced by the two types of responder T cells (Figs. 2A and 2B). Most of the sorted CD4+CD25low T cells showed activated phenotype, significantly lower expression of CD45RA (Mann-U-Whitney test, p = 0.0022) and significantly higher expression of CD45RO (p = 0.002) (Figure 2A). In addition, significantly more CD4+CD25low T cells expressed HLA DR and CD69 compared to CD4+CD25- T cells (Mann-U-Whitney test, p = 0.038 and p = 0.0048, respectively). Expression of HLA DQ showed borderline significance also in favor of CD4+CD25low compared to CD4+CD25- T cells (p = 0.057). CD4+CD25low T cells produced significantly more IFN-gamma and IL-2 compared to CD4+CD25- T cells even after mild stimulation provided by anti-human CD3-coated beads (1 µg/ml) (Mann-U-Whitney test, p = 0.015 and p = 0.027, respectively, Figure 2B), as well as for IL-10 (data not shown). Both CD4+CD25- and CD4+CD25low responder T cells were cultured either in the presence or absence of Tregs following 18 separate stimuli (Table 1). The percentage of suppression, averaged over six individual measurements, was plotted as a radar chart to accommodate all the data points (Figure 3A). The percentage of suppression increases with the distance from the center. Using a generalized linear model (GLM), neither the type or number of APC nor time in culture were shown to influence the extent of suppression, even though the strength of TCR stimulation almost reached statistical significance (p = 0.057). However, the difference in suppression between CD25- and CD25low was highly significant, indicating that the type of responder T cell was found to be the major predictor variable for percentage of suppression (p = 0.003, n = 6 subjects, by GLM).

Figure 1
Isolation of human CD4+CD25high and CD4+CD25low T cells from PBMC.
Figure 2
Analysis of surface molecules and cytokine production by sorted T cells.
Figure 3
CD4+CD25low T cells were suppressed less than CD4+CD25- in in vitro co-culture with Tregs.
Table 1
Tested variables in in vitro human suppression assay.

Assays with CD4+CD25low T cells as responders generally gave lower suppression values than assays with CD4+CD25- T cells (radar chart, Figure 3A). This highlights an intrinsic difference between the two types of responder T cells. For subsequent experiments, we used 1 µg anti-human CD3-coated beads, 1 x irrPBMC and cultures cells for 3 days (* in Figure 3A). Although few other conditions gave a substantial difference in suppression between the two responder T cell subsets as well, the chosen conditions were considered optimal as both responder T cell subsets show the most consistent suppression results with the lowest s.e.m. amongst the 18 different treatments for each of the responder T cell subsets. The corresponding cpm values for these specific optimal conditions are presented in Figure 3B and corresponding percentage of suppression in Figure 3C. In addition, this combination of stimuli was used for T cells isolated from both healthy control and T1D-related subject groups (Figure 6).

Figure 6
RO-T1D and aAb+ve unaffected subjects show dramatic decrease in suppression of CD4+CD25low-Tcell proliferation by Tregs.

CD4+CD25low T cells proliferate more than CD4+CD25- T cells

The proliferation profiles of the CD4+CD25- and CD4+CD25low responders were assessed both in single and co-culture. Responder T cells were labeled with CFSE and cultured alone and with Tregs in the presence of 1 µg anti-human CD3 beads and 1xirrPBMC for 3 days. CFSE-labeled responder T cells were gated from other cells in the culture and analyzed for cell division. We found that CD4+CD25low responder T cells divided more than CD4+CD25- T cells in both single culture and co-culture (Figure 4A). The normalized mean number of divisions (40) for CD4+CD25- T cells in single and co-culture were 0.73±0.19 and 0.16±0.04 respectively, whereas for CD4+CD25low T cells the corresponding values were 1.12±0.2 and 0.5±0.07. These results show that CD4+CD25low T cells divided ~1.5 times more in single culture and 3 times more in co-culture compared to CD4+CD25- T cells. The ratio of mitotic divisions in co-culture versus single culture is 0.23±0.05 for CD4+CD25- T cells and 0.46±0.06 for CD4+CD25low T cells (Figure 4B, p<0.05, n = 3).

Figure 4
CD4+CD25low responder T cells proliferate faster and are harder to suppress.

Different kinetics of IL-2 production in CD4+CD25- and CD4+CD25low T cells

Counts per minute at three different time points were used to record the distinct proliferation of the two responder T-cell subsets on the stimulation. CD4+CD25- T cells proliferated significantly less compared to CD4+CD25low T cells at all time points (p<0.05 at 24 hours and p<0.01 at later time points, Figure 5A). We also measured % of dead cells in single and co-culture at three time points during culturing of both responder T cell subsets (Figure 5B). CD4+CD25- were dying at slightly higher rate in single culture compared to CD4+CD25low T cells during the first 48 hours, which changed at 72 hours. In co-culture, the faster death rate of CD4+CD25- T cells at 24 hours compared to CD4+CD25low flipped at 48 and 72 hours, when CD4+CD25low started dying faster (Figure 5B). Since it has been reported that IL-2 is directly involved in the proliferation of responder T cells [23] and that human Tregs are dependent on available IL-2 for their suppressor activity [24], we monitored IL-2 production in both responder T-cell subsets at 4 different time points. This was done using RT-PCR (Figure 5C). CD4+CD25low T cells responded by transcribing IL-2 mRNA faster/sooner than CD4+CD25- T cells. At 8 hours CD4+CD25low T cells showed >2 fold increase in IL-2 mRNA production compared to CD4+CD25- T cells (t-test, p = 0.02). At 20 and 48 hours, IL-2 mRNA production in CD4+CD25- was higher than in CD4+CD25low T cells at the same time points. However, at the last measured time point (72 hours), CD4+CD25low T cells increased IL-2 expression almost 2 fold compared to CD4+CD25- T cells reaching significance again (t-test, p = 0.038). This can be explained by bimodal pattern of IL-2 expression in CD4+CD25low T cells. Namely, CD4+CD25low T cells express IL-2 sooner, proliferate faster, and start dying later. CD4+CD25low T cells that survive begin rapid IL-2 production and proliferation, while CD4+CD25- T cells responded at a slower rate. Furthermore, proliferation and suppression of both T cell responder subsets under different concentrations of recombinant IL-2 or anti-human IL-2 was also recorded. Addition of 20 IU/ml of recombinant IL-2 to both single and co-culture of CD4+CD25- responder T cells was able to produce the same proliferation ratio between single and co-culture as seen in CD4+CD25low T cells without exogenous IL-2 (Figure 5D). When single and co-cultured CD4+CD25low T cells were treated with different concentrations of anti-human IL-2, the proliferation ratio, seen in single and co-cultured CD4+CD25-, was achieved with 3 µg/ml of anti-human IL-2 (Figure 5E). Thus, we were able to reconstitute the observed proliferation differences between single culture and co-cultures for the alternative responder T cells by addition of recombinant IL-2 to CD25- assays or by deprivation of IL-2 in CD25low assays. These experiments confirm existing differences in kinetics of IL-2 production between CD4+CD25- and CD4+CD25low T cells. It should be noted that experimental conditions were slightly changed because of potential changes in viability. Thus, in this series of experiments with addition of IL-2 and anti-IL-2 cells were in culture 54 hours, pulsed and left in culture for additional 15 hours (totaling 70 hours).

Figure 5
Time-course experiment showed different dynamic of proliferation, death and IL2-production in CD4+CD25- and CD4+CD25low T-cells.

CD4+CD25low T cells are harder to suppress in T1D-related subjects

The optimal suppression assay (asterix in Figure 3) was then applied to our cohort population. The only difference from the assay developed on anonymous leukopacks was the ratio between Tregs and responders, which we further optimized (Figure S1) due to limited number of available FACS-isolated Tregs from pediatric subjects. The optimal ratio was determined to be 1[ratio]10. This ratio was then used for measurement of Treg function across subject groups. Such high ratio additionally indicated purity of the Treg subset. There was statistically significant difference in suppressive potential of CD4+CD25- T cells between control, recent-onset (RO) T1D and aAb+ve subjects (Kruskal-Wallis test, p = 0.012). However, the difference was even more pronounced for CD4+CD25low T cells (Kruskal-Wallis test, p = 0.0001). In healthy control subjects (n = 14), Tregs showed lower suppressive potential of CD4+CD25low compared to CD4+CD25- T cells (37.6±7.2 vs 50.2±7.3%, p = 0.017, Figure 6B vs. 6A), corroborating results generated with leukopacks. The difference in suppression of CD4+CD25low and CD4+CD25- was also significantly differed in both RO T1D subjects (−22.2±9.6 vs. 17.8±5.5, respectively, p = 0.0025, n = 11, Figure 6B vs vs6A)6A) and in aAb-positive subjects (9.9±8.0 vs. 32.0±8.1%, respectively, p = 0.008, n = 12, Figure 6B vs vs6A).6A). Control of CD4+CD25low T cells proliferation was, therefore, decreased in all three groups, but, seriously compromised only in RO T1D subjects (Kruskal-Wallis test, p = 0.0001, Figure 6B).

Discussion

In organ-specific autoimmune disease, the affected organ is largely infiltrated with T lymphocytes by specific homing. At the site, further activation, proliferation, survival and effector function of autoreactive T cells results in tissue damage. It is likely that the autoreactive T cells belong to CD4+CD25low T cell population. Tregs are known to regulate these activated T cells, thereby inhibiting their effector function. Although both in vitro and in vivo regulation of these autoreactive T cells by Tregs has been studied in animal models for many autoimmune diseases, fewer human in vitro studies have been performed. Studies exploring CD4+CD25low T cells as responders in human in vitro suppression assays are scarce [25], [26]. The majority of studies were performed with either naïve CD4+CD25- T cells or PBMCs as responders. It has been acknowledged that difference between naïve and activated cells exist, as several studies have shown that CD4+CD25low T cells have a different activation status than in vitro-activated naïve T cells [27], [28], [29], [30], [31]. Naive T cells, once activated, proliferate and differentiate into effector T cells that differ from naive cells with respect to faster kinetics of their response to re-stimulation. In addition, activated cells are less dependent on co-stimulation in exerting their effector function (cytokine production, migration, proliferation) [32]. In the present study we set out to explore in-vitro suppression exercised by FACS-isolated Tregs on two types of human responder T cells: naïve, CD4+CD25- and in vivo activated, CD4+CD25low T cells.

The strength of stimuli in co-culture with Tregs dictates whether suppression will occur or not. With high TCR stimulation, suppression is either low or abrogated [33]. When the 18 different stimuli were examined, irrespective of the strength of TCR signal or number and types of irradiated APC cells used in co-culture, the strongest statistical difference in suppression we found to be explained by the type of responder T cells (p<0.003). The strength of TCR signal used in this study had some, rather weak, effect on suppression (p<0.057). Based on these results, we can conclude that the type (nature) of the responder T cells has the greatest impact on suppression assay.

Maintenance of T cell homeostasis is critical in the well-orchestrated immune system and Tregs are one of the key players. They depend on IL-2 produced by other T cells for their development, proliferation and efficient function [34]. One of the indicators of suppression by Tregs is the inhibition of transcription of this proliferative cytokine in responder T cells [35]. Differential suppression of CD4+CD25- and CD4+CD25low responders by the same Tregs could be due to an unequal inhibition of IL-2 transcript in the two responder T cells. As CD4+CD25low T cells have already been activated, they react faster than naïve T cells on the same stimulus. Our results showed that CD4+CD25- and CD4+CD25low responder T cells produced different amounts of IL-2 mRNA as well as IL-4 (data not shown). In vitro stimulated, CFSE-positive CD4+CD25low responder T cells began IL-2 production earlier than CD25-, suggesting different kinetics between the two responder T cells [32]. IL-2 production decreased up to 48 hours in culture, while death rate increased (Figure 5). However, at 72 hours in culture, CD4+CD25low responder T cells that survived began a new cycle of IL-2 production and proliferation. This could be explained by bimodal IL-2 expression hypothesis [36]. Bimodal IL-2 expression could be achieved through positive feedback loops of upregulated IL-2R alfa [37], which is differently expressed in CD4+CD25- and CD4+CD25low T cells. In addition, it has been reported that NFATc2 transcription factor, shown as powerful molecular switch of IL-2 expression, shows a bimodal expression [38].

Another possible explanation for reduced suppression of CD4+CD25low responder T cells is that with further activation, the pre-activation status of these cells make them divide more easily compared to CD4+CD25- T cells. The proliferation profile of CFSE-labeled responder T cells under the same stimuli (Figure 4) showed that CD4+CD25low T cells divide significantly more in co-culture than CD4+CD25- T cells. The increased proliferation of CD4+CD25low T cells may play a role in vivo and explain the existence of this expanded T-cell subset in autoimmune disease patients [39], [40]. Several autoimmune patient studies showed that CD4+CD25low T cells expressed increased levels of several surface molecules like CD95 [41], CD71 [42], [43], CD26 [27], CD29 [43] and CD28 [44]. These studies clearly indicate that CD4+CD25low T cells from autoimmune patients are different from in vitro activated naïve-T cells and emphasize the importance of using in vivo activated T cells (CD4+CD25low) as responders in in vitro suppression studies. Our results presented in Figure 6 show significant decrease in control of CD4+CD25- T cell proliferation by Tregs isolated from RO T1D subjects, as we showed earlier [45]. In the present study we show that this decrease was even more prominent with CD4+CD25low T cells as responders. In aAb-positive subjects, there was a clear difference in suppressive potential of CD4+CD25- compared to CD4+CD25low T cells, which could offer an explanation for impaired sensitivity of responder T cells to the suppressive effect of Tregs in autoimmune diseases reported by increasing number of studies [15], [16], [17], [46]. The role of IL-2 is essential for Treg function. Therefore the local cytokine milieu that depends on the activation status of effector T cells, has crucial role on Treg function. Here we showed that our optimized in vitro suppression assay, if set up with both naïve and in vivo activated T cells as responders, can identify inability of Tregs to control activated T cell proliferation before symptoms of autoimmune disease appear.

Although the generated results were consistent, it should be noted that the isolation of Tregs was performed based on CD25 expression, a surface marker that is not unique to Tregs. However, there is no unique human surface marker to date that would distinguish Tregs from non-regulatory T cells. FACS isolation based on CD25 and CD127 (and especially solely based on CD127) did not show higher suppressive potential in our hands compared to CD4CD25high T cells (data not shown). Other groups have also reported on the unclear advantage of isolation based on CD127/CD25 compared to the use of CD25 [47], [48], [49]. Despite the impurity of Tregs, our results show divergence between the two responder cells, clearly pointing to differences in the two types of cellular interaction that occurs in co-culture.

In summary, based on extensive study presented here, we concluded that human in vivo activated T cells and naïve T cells behave differently in in vitro suppression assays when set up with natural Tregs. The type of responder cells is an important variable of suppression assay, which can explain resistance to regulatory T cell-mediated suppression noticed by several groups. The increased production of IL-2 by CD4+CD25low T cells might explain the observed differences in suppression. We show that the use of this in vitro suppression assay with both naïve and in vivo-activated T cells as responders is an excellent tool in the recognition of an early state in immune imbalance. Further investigation into the pleiotropic nature of suppression with different responder T cells in T1D and other autoimmune diseases may give more insight into Tregs function in diseased conditions.

Materials and Methods

Media, reagents and antibodies

Anti-human CD4-PE-Cy5, anti-human CD25-PE (M-A251), anti-human CD14-FITC, anti-human CD32-FITC, anti-humanCD116-FITC, anti-human CD8-FITC, anti-human CD28 (CD28.2) and Human Th1/Th2 cytokine cytometric bead array (CBA) kit were purchased from BD Bioscience, CA. L-glutamine, sodium pyruvate, HEPES, penicillin/streptomycin were purchased from Life Technologies, MD. Anti-human CD3 (UCHT1) was purchased from Ancell, MN. Anti-human CD4 microbeads and anti-human CD2-magnetic beads were purchased from Miltenyl Biotech, CA. Tosylactivated magnetic beads used for coating with anti-human CD3 were purchased from Dynal Biotech (Norway) and the procedure was done according to manufacturer's protocol using 0.5 µg, 1 µg and 2.5 µg anti-human CD3 per 107 beads for coating. Human AB serum was purchased from Atlanta Biologicals, GA. RPMI 1640 was purchased from BioWhittaker, MD. Human recombinant IL-2 was purchased from BD Biosciences and anti-human IL-2 from R&D Systems.

Cell isolation

PBMC were isolated from human leukopacks (n = 6) kindly provided by the Blood Center of Wisconsin, Milwaukee by Ficoll-Hypaque (Amersham Pharmacia Biotech, NJ) density gradient centrifugation. The CD4+ T cells were isolated from 9–10×108 PBMC by MACS sorting using anti-human CD4 microbeads. The isolated CD4+ (1–2×108) T cells were stained for FACS isolation as decribed earlier [45]. PBMC from T1D-related subject groups did not undergo MACS sorting, they were directly stained for FACS isolation. Gates for CD4+CD25low were made based on Fluorochrome Minus One. Gating and purity of isolated cells is presented in Figure 1a. T cell-depleted accessory cells (TdAc) were isolated by negative selection of PBMC incubated with anti-human CD2-coated beads (Miltenyl Biotech, CA) followed by MACS sorting.

Human subjects

Thirty seven subjects were ascertained primarily through the diabetes clinic at Children's Hospital of Wisconsin (CHW). Inclusion criteria for control subjects were a random blood glucose <110 mg/dl, no personal and family history of type 1 diabetes and an absence of diabetes-specific autoantibodies (to GAD, insulin and IA-2). Diabetes was defined according to accepted criteria: 1. Symptoms of diabetes plus casual plasma glucose concentration An external file that holds a picture, illustration, etc.
Object name is pone.0015154.e001.jpg200 mg/dl (11.1 mmol/l) OR 2. FPG An external file that holds a picture, illustration, etc.
Object name is pone.0015154.e002.jpg126 mg/dl (7.0 mmol/l). The protocol was approved by the CHW institutional review board (IRB) and participants and/or their parents (guardians) provided written informed consent and completed a questionnaire. All subjects had T1D-specific autoantibodies measured at the recruitment visit. (Table S1 presents the demographic data).

Cell culture

Both CD4+CD25- and CD4+CD25low (104 cells/well) were cultured in RPMI 1640 media supplemented with 2 mM L-glutamine, 5 mM HEPES, 100 U/ml penicillin/streptomycin, 0.5 mM sodium pyruvate and 10% human AB serum. Cells were stimulated with anti-human CD3 coated beads (0.5, 1, 2.5 µg, 3 beads/cell) in U-bottom 96 well plates (Costar, NY) in the presence of three variations of autologous irradiated APC: 4 x PBMC, 4 x TdAc or 1 x PBMC for 3 or 5 days. Irradiation was performed at dose of 5000rad. For the suppression assays, Treg cells were co-cultured with CD4+CD25- or CD4+CD25low at a 1[ratio]1 ratio (Treg:Tresponder). At the end of the culture (3 or 5 days), cells were pulsed with 1 µCi of [3H]thymidine (Amersham Pharmacia Biotech, NJ) and harvested after 16 hours. The cpms per well were determined using a scintillation counter (Top Count NXT, Packard, CT). However, in experiments with added IL-2 and anti-IL-2, cells were culture for 54 hours (because of anticipated changes in viability), pulsed and cultured for another 16 hours.

Carboxyfluoroscein Succinimidyl Ester (CFSE) Staining

CFSE is a vital stain which, upon entering cells, undergoes esterase cleavage and diffuses throughout the cytoplasm. As cells divide, the CFSE is split equally between the daughter cells resulting in diminished CFSE signal detection in flow-cytometric analysis. CFSE was added at a final concentration of 125 nM to 1–2×106/ml of responder T cells and incubated for 15 minutes at room temperature in the dark. The reaction was stopped by adding an equal volume of cold media containing 10% serum and the cells were washed twice with the same media. CFSE-labeled responder T cells were only analyzed for 3 days since by 5 days fractions of responders could not be distinguished from unstained cells. Analysis of divisions of responder T cells was done using the ModFit software (Verity Software House, USA).

Mortality assay

After 3 days of culture, cells were washed and stained with 7-aminoactinomycin D (7AAD) and analyzed by Flow Cytometry. The population stained with 7AAD has been found to correspond to dead cells. Responder cells in both single and co-culture were assessed for death. The percentage of increase in death in co-culture is X = [Ac-As]/As x 100, where As  = dead cells in single culture, Ac  = dead cells in co-culture.

Flow cytometry

For all flow-cytometric analyses, cells were stained with the appropriate combination of monoclonal antibodies in PBS containing 0.5% BSA and 2 mM EDTA for 20 minutes at 4°C. After washing, the labeled cells were analyzed or fixed with 2% paraformaldehyde, then analyzed using a FACS Calibur with CellQuest or FACSDIVA software. Cytokines were measured from cell culture supernatants after 48 hours of stimulation (1 µg anti-human CD3 beads and 1 x irrPBMC) with CBA assay kit according to manufacturer's protocol (BD Bioscience). Foxp3 expression was measured by Flow Cytometry using intracellular Foxp3 staining kit from eBioscience, USA.

RT–PCR

Total cellular RNA was extracted from the sorted CFSE-labeled responder cells after 24, 48 and 72 hours in culture with Trizol reagent. Total RNA was processed as described earlier [50]. The primer sequences were as follows; IL-2: 5′-CAGTGCACCTACTTCAAGTTCTACA-3′ and 5′-CCTGGTGAGTTTGGGATTCTTGTAA-3′. The fold change of IL-2 mRNA has been calculated using the following formula. Fold Change  = 2-ΔCT, where ΔCT  = CTIL-2 -CTGAPDH. Percentage reduction in IL-2 mRNA expression from single to co-culture is [(Xs-Xc)/Xs] x 100, where Xs  = fold change of IL-2 in single culture, Xc  = fold change of IL-2 in co-culture.

Time-course experiment

Separate plates were set up with CFSE-stained both CD4+CD25- and CD4+CD25low T cells as responders that were isolated from additional leukopacks. Cells were collected at 24+16 hours, 48+16 hours and 72+16 hours, stained with 7AAD, acquired for analysis and the rest was sorted as CFSE+ve cells on FACSVantage or FACS Aria to eliminate Tregs, irradiated PBMC (5000 rad) and anti-human CD3-coated beads. FACS-sorted responder T cells were put in Trizol and kept at -80°C until RNA isolation was performed. At each time point, supernatants were taken out from wells after which they were pulsed for measuring of 3H-thymidine incorporation. Supernatants were kept at -80°C until cytokine measurement using CBA assay was performed.

Cytokine measurement

Measurement of cytokine levels was performed using the Cytometric Bead Array (CBA) Human Th1/Th2 Cytokine Kit (BD Biosciences). Supernatants were thawed and 50 µl was used for simultaneous measurement of following cytokines: INF-g, TNF-a, IL-5, IL-4 and IL-2. The assay was performed according to the manufacturer's protocol. The samples were acquired on a FACSCalibur (BD Biosciences) following the cytometer setup protocol. The FACS data was analyzed using the CBA 6 bead analysis software (BD Biosciences).

Statistical analysis

We employed a generalized linear model (GLM) with the dependent variable being the percentage suppression [(s-c)/s] x 100%, where s = cpm in single culture and c = cpm in co-culture. The factors were strength of stimulation (three levels, 0.5, 1 and 2 µg/ml anti-CD3 coated beads), type and amount of irradiated APC (1X PBMC, 4X PBMC and 4X TdAC), days of co-culture (3 or 5 days) and type of responder T cells (CD4+CD25- or CD4+CD25low T cells). An analysis of variance was performed.

From the CFSE data the numbers of cells in each generation were calculated using the software ModFit. The normalized mean number of division that cells have undergone was calculated using method of De Boer and Perelson, where Xn(t)  = the number of cells undergone n divisions by time t [51]. Since after n divisions, each cell gave rise to a maximum 2n progeny under ideal conditions, An external file that holds a picture, illustration, etc.
Object name is pone.0015154.e003.jpg = (is) the number of precursors that would have generated Xn(t) cells. Total number of cell division that Xn(t) cells have undergone is expressed as nAn external file that holds a picture, illustration, etc.
Object name is pone.0015154.e004.jpg. So, the number of precursors that would have generated all the current cell population is An external file that holds a picture, illustration, etc.
Object name is pone.0015154.e005.jpg and the total number of cell divisions for the entire current cell population is An external file that holds a picture, illustration, etc.
Object name is pone.0015154.e006.jpg. The normalized mean number of division cells have undergone is hence, An external file that holds a picture, illustration, etc.
Object name is pone.0015154.e007.jpg.

Supporting Information

Figure S1

Titration of responder T cells in suppression assay. CD4+CD25- were FACS isolated from leukopacks drawn from healthy volunteers and cells were stimulated with 1 µg/ml anti-human CD3 with 1x irradiated PBMC as APC for 3 days. Since extent of suppression began decreasing at 1[ratio]16 ratio, 1[ratio]10 was consistently performed in experiments with T1D-relevant subject groups.

(TIF)

Table S1

Demographic data for T1D-related subject groups

(DOC)

Acknowledgments

The authors thank Marylin Koppen and Joanna Kramer for coordinating recruitment of the subjects and Karen Zeqiri for administrative help.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This study was supported by Max McGee Fund, Children's Research Institute, a grant from GCRC MO1-RR00058 from the National Institutes of Health and RAC MCW grant (409-1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol. 2003;171:6323–6327. [PubMed]
2. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151–1164. [PubMed]
3. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000;12:431–440. [PubMed]
4. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000;192:295–302. [PMC free article] [PubMed]
5. Suri-Payer E, Amar AZ, Thornton AM, Shevach EM. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol. 1998;160:1212–1218. [PubMed]
6. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001;167:1245–1253. [PubMed]
7. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899–911. [PubMed]
8. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203:1701–1711. [PMC free article] [PubMed]
9. Ehst BD, Ingulli E, Jenkins MK. Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection. Am J Transplant. 2003;3:1355–1362. [PubMed]
10. Tran DQ, Glass DD, Uzel G, Darnell DA, Spalding C, et al. Analysis of adhesion molecules, target cells, and role of IL-2 in human FOXP3+ regulatory T cell suppressor function. J Immunol. 2009;182:2929–2938. [PMC free article] [PubMed]
11. Liu MF, Wang CR, Fung LL, Wu CR. Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol. 2004;59:198–202. [PubMed]
12. Cao D, Malmstrom V, Baecher-Allan C, Hafler D, Klareskog L, et al. Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol. 2003;33:215–223. [PubMed]
13. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004;199:971–979. [PMC free article] [PubMed]
14. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes. 2005;54:92–99. [PubMed]
15. D'Alise AM, Auyeung V, Feuerer M, Nishio J, Fontenot J, et al. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci U S A. 2008;105:19857–19862. [PubMed]
16. Venigalla RK, Tretter T, Krienke S, Max R, Eckstein V, et al. Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127-/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum. 2008;58:2120–2130. [PubMed]
17. Lawson JM, Tremble J, Dayan C, Beyan H, Leslie RD, et al. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin Exp Immunol. 2008;154:353–359. [PubMed]
18. Jin Y, Chen X, Podolsky R, Hopkins D, Makala LH, et al. APC dysfunction is correlated with defective suppression of T cell proliferation in human type 1 diabetes. Clin Immunol. 2009;130:272–279. [PMC free article] [PubMed]
19. Herman AE, Freeman GJ, Mathis D, Benoist C. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med. 2004;199:1479–1489. [PMC free article] [PubMed]
20. Kumanogoh A, Wang X, Lee I, Watanabe C, Kamanaka M, et al. Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. J Immunol. 2001;166:353–360. [PubMed]
21. Hansen JD, Du Pasquier L, Lefranc MP, Lopez V, Benmansour A, et al. The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective. Mol Immunol. 2009;46:457–472. [PubMed]
22. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001;193:1303–1310. [PMC free article] [PubMed]
23. Cantrell DA, Smith KA. The interleukin-2 T-cell system: a new cell growth model. Science. 1984;224:1312–1316. [PubMed]
24. Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev. 2001;182:58–67. [PubMed]
25. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol. 2005;174:1783–1786. [PubMed]
26. Lundgren A, Suri-Payer E, Enarsson K, Svennerholm AM, Lundin BS. Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun. 2003;71:1755–1762. [PMC free article] [PubMed]
27. Khoury SJ, Guttmann CR, Orav EJ, Kikinis R, Jolesz FA, et al. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol. 2000;57:1183–1189. [PubMed]
28. Jensen J, Langkilde AR, Fenst C, Nicolaisen MS, Roed HG, et al. CD4 T cell activation and disease activity at onset of multiple sclerosis. J Neuroimmunol. 2004;149:202–209. [PubMed]
29. Peakman M, Leslie RD, Alviggi L, Hawa M, Vergani D. Persistent activation of CD8+ T-cells characterizes prediabetic twins. Diabetes Care. 1996;19:1177–1184. [PubMed]
30. Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity. 1998;8:89–95. [PubMed]
31. Strauss L, Bergmann C, Whiteside TL. Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol. 2009;182:1469–1480. [PubMed]
32. Croft M, Bradley LM, Swain SL. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol. 1994;152:2675–2685. [PubMed]
33. Baecher-Allan C, Viglietta V, Hafler DA. Inhibition of human CD4(+)CD25(+high) regulatory T cell function. J Immunol. 2002;169:6210–6217. [PubMed]
34. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201:723–735. [PMC free article] [PubMed]
35. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol. 2004;172:6519–6523. [PubMed]
36. May T, Eccleston L, Herrmann S, Hauser H, Goncalves J, et al. Bimodal and hysteretic expression in mammalian cells from a synthetic gene circuit. PLoS One. 2008;3:e2372. [PMC free article] [PubMed]
37. Busse D, de la Rosa M, Hobiger K, Thurley K, Flossdorf M, et al. Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. Proc Natl Acad Sci U S A. 2010;107:3058–3063. [PubMed]
38. Podtschaske M, Benary U, Zwinger S, Hofer T, Radbruch A, et al. Digital NFATc2 activation per cell transforms graded T cell receptor activation into an all-or-none IL-2 expression. PLoS One. 2007;2:e935. [PMC free article] [PubMed]
39. Bijl M, Horst G, Limburg PC, Kallenberg CG. Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity. Lupus. 2001;10:866–872. [PubMed]
40. Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. 2003;21:273–276. [PubMed]
41. Amasaki Y, Kobayashi S, Takeda T, Ogura N, Jodo S, et al. Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia. Clin Exp Immunol. 1995;99:245–250. [PubMed]
42. Black AP, Bhayani H, Ryder CA, Gardner-Medwin JM, Southwood TR. T-cell activation without proliferation in juvenile idiopathic arthritis. Arthritis Res. 2002;4:177–183. [PMC free article] [PubMed]
43. Hidaka T, Suzuki K, Matsuki Y, Takamizawa-Matsumoto M, Okada M, et al. Changes in CD4+ T lymphocyte subsets in circulating blood and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. Ther Apher. 1999;3:178–185. [PubMed]
44. Salazar-Fontana LI, Sanz E, Merida I, Zea A, Sanchez-Atrio A, et al. Cell surface CD28 levels define four CD4+ T cell subsets: abnormal expression in rheumatoid arthritis. Clin Immunol. 2001;99:253–265. [PubMed]
45. Glisic-Milosavljevic S, Waukau J, Jailwala P, Jana S, Khoo HJ, et al. At-risk and recent-onset type 1 diabetic subjects have increased apoptosis in the CD4+CD25+ T-cell fraction. PLoS One. 2007;2:e146. [PMC free article] [PubMed]
46. van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 2004;50:2775–2785. [PubMed]
47. Klein S, Kretz CC, Krammer PH, Kuhn A. CD127(low/-) and FoxP3(+) expression levels characterize different regulatory T-cell populations in human peripheral blood. J Invest Dermatol. 130:492–499. [PubMed]
48. Long SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes. 59:407–415. [PMC free article] [PubMed]
49. Hoffman P ER, Boeld TJ, Doser K, Piseshka B, Andreesan R, Edinger M. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood. 2006;108:4260–4267. [PubMed]
50. Jailwala P, Waukau J, Glisic S, Jana S, Ehlenbach S, et al. Apoptosis of CD4+ CD25(high) T cells in type 1 diabetes may be partially mediated by IL-2 deprivation. PLoS One. 2009;4:e6527. [PMC free article] [PubMed]
51. De Boer RJ, Perelson AS. Estimating division and death rates from CFSE data. Journal of Computational and Applied Mathematics Special Issue on Mathematics Applied to Immunology. 2005;184:140–164.

Articles from PLoS ONE are provided here courtesy of Public Library of Science